Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday May 31.
11 Things To Watch In The Week Ahead: Dollar General (NYSE:DG), Bank of America (NYSE:BAC), JPMorgan (NYSE:JPM), Brown-Forman (NYSE:BF.A), (NYSE:BF.B), Ascena (NASDAQ:ASNA). Other stocks mentioned: Barrick Gold (NYSE:ABX), Sony (NYSE:SNE), Lions Gate Entertainment (LGF)
With the Dow down on Friday over 200 points, Cramer believes that what is responsible for the decline is good news, not bad news. When there is positive economic data, hedge funds fear the Fed might end its policy of low interest rates, and as a result, they tend to dump certain stocks, like high yielders, MLPs and REITs. Cramer would be cautious about dividend stocks, and look at banks and industrials. Cramer discussed the game plan for the week ahead.
Chinese non-manufacturing PMI is going to be released on Sunday night. Cramer expects it to be disappointing. However, if it is decent, minerals could rocket higher.
Eurozone Manufacturing PMI needs to be not worse than the previous number for a rally.
Dollar General (DG), like other dollar stores, has been doing well lately. Cramer expects earnings to be decent.
Dallas Fed President Richard Fisher's Speech could be a "nightmare" for stocks, since he tends to be "hawkish" on the Fed's moves.
Ascena (ASNA) has rallied, and it can't afford to disappoint.
ADP Employment Number is often seen as a precursor to the major employment number, but Cramer doesn't think it is. He would ignore it entirely.
Philadelphia Fed President Charles Plosser speaks. He is loved by short sellers and "this guy is worse than Fisher (Dallas Fed President) in his his impact on stocks." Plosser has expressed worries about inflation.
ECB Meeting: Europe seems to be bottoming, but growth is needed.
Employment Number: Many are expecting the unemployment rate to be 7.5%, but anything to the north of this number will slam both the bond and stock markets.
Cramer took some calls:
Lions Gate Entertainment (LGF): "You are late to the party," Cramer said. The stock has no real edge now that the story has been told. He can't see it dipping soon to provide a buying opportunity, either.
Sony (SNE): Cramer told an investor to take gains in half the position on Monday.
Barrick Gold (ABX): Although Cramer thinks gold prices might be bottoming, he still would not take the risk of buying mining stocks.
Celldex (CLDX) is a biotech company that concentrates on cancer immunotherapy, or finding ways to use the body's own defenses to fight cancer cells. This is one of the hottest areas in oncology, and CLDX has risen 90% since the beginning of the year on very positive data. CLDX focuses on treating some of the deadliest and hardest to treat cancers, such as a rare form of breast cancer. The response rate from CLDX's treatment was 32% compared to 13% with existing treatments. Survival rates are twice as long, according to some studies, and the drug could be approved by 2015. The company has another treatment to combat a very rare form of brain cancer, and in some studies, the survival rates for patients were twice as long. This drug is also expected to be approved by the FDA in 2015, and both treatments could bring a billion in annual revenue. Cramer thinks the stock could run from $13 to $20 if these drugs are approved, but he emphasized that these are speculative stocks and should be bought gradually on declines.
Wall Street analysts like clean, uncomplicated stories, and that is why stock prices tend to rise when a spin-off is announced. Occidental Petroleum (OXY), a holding in Cramer's charitable trust, may be the next successful break-up story in the oil and gas sector. The company has oil and gas assets all over the world. Domestically, it has significant holdings in the Permian Basin and in the Monterey shale in California. OXY also has a commodity chemical business. The company is preparing to have a strategic review in late July. Cramer thinks OXY should sell its holdings in the Middle East and North Africa and use the money to buy back shares. In the U.S, OXY could split into a growth segment, which includes its holdings in the Permian basin, and a more aggressive, growth oriented segment with assets in unconventional plays like the Monterey and the Bakken shales. Cramer predicts that the value of these segments if divided could bring the stock up 53% higher than its current level.
Cramer took some calls:
National Oilwell Varco (NOV) is a great equipment company and has recovered from its lackluster quarter.
Linn Energy (LINE) represents value, even though there is a rotation out of these kinds of stocks.
TearLab (TEAR) develops "lab-on-a-chip" technology that enables eye doctors to diagnose eye problems by collecting tears. The chip eliminates the need to send tests to the lab and cuts the waiting time. The main test is for dry eye, a condition suffered by as many as 40 million people in the U.S. Only 5% are treated for it because of the inconvenience of standard testing, but it is not necessarily a minor problem, since it can lead to increased eye infections and vision problems. TEAR sells disposal chips for its machine, and the "razor blade" business model has been responsible for the doubling of its gross margins. The stock has risen 157% in just 6 months, but Cramer thinks TEAR could rise higher given the growing popularity of its products; the company's management says it has needed to triple manufacturing capacity to keep up with demand. Cramer thinks the stock could rise 43% from its current level, would use limit orders when buying, and would wait for a pullback.
Tesla Motors (NASDAQ:TSLA)
Cramer test drove a Tesla (TSLA) and while he gave the car raving reviews, he doesn't know if the stock, which has tripled, is worth buying. Currently, it is not profitable without government subsidies, and while it might not need this help forever, TSLA is a cult stock that has roared. However, it is also a dangerous short. Cramer is positively undecided on TSLA; he leaves the option of whether to buy or stay away up to the viewer.
Jim Cramer's Action Alerts PLUS: Trade right alongside a Wall Street pro! Start your 14-day FREE trial today.
Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.